Klinika Oczna

Transscleral administration of lutein in patients with dry age-related macular degeneration

  1. Ophthalmic University Hospital (SPKSO), Warsaw, Poland

  2. Department of Ophthalmology, Medical University of Warsaw, Poland

  3. Laser Eye Microsurgery Centre in Warsaw, Poland

KLINIKA OCZNA 2026, 128, 4: 1-7

Data publikacji online: 2026/11/21
Plik artykułu
KO-00594.pdf


Introduction

There are several different methods of drug administration into ocular tissues, including topical eyedrops, periocular injections, intravitreal injections, and systemic drugs. However, to maintain sufficient and constant concentration of the drug in the retina or vitreous, large amounts or invasive injections that increase the chance of serious complications are necessary. Iontophoresis is a technique that has been utilised in different fields of medicine for years and allows drug administration directly into the tissues [1]. It acts by enhancing transport of ionised biological molecules, such as pharmaceuticals, between two sides of the membrane or tissue based on the electrical current [2]. To establish target quantities of the substance to be delivered, protocols including application time, electric current, and applicator contact area are used [3].
Two mechanisms allowing drug penetration are involved: electrorepulsion (ions move in an ordered way under the influence of an electric field) and electroosmosis (liquid moves from an anode to a cathode through a membrane under an applied electric potential) [2].

Transscleral iontophoresis is a type of ocular ionto-phoresis in which a drug can be administered noninvasively through the eyeball wall [4]. It acts through bypassing the lens-iris barrier, which normally separates the anterior and posterior segments from topical drug penetration, and allows achievement of desired concentrations of the pharmaceutical in the retina or vitreous of the eye without injection [1]. Hence, the risk of infection or inflammation inside the eye is reduced. This method also increases the patients’ tolerability and is characterised by very rapid recovery [5]. Scleral iontophoresis has been tested and confirmed as an effective method of lutein delivery into the human retina [6].

Age-related macular degeneration (AMD) is one of the most frequent causes of visual loss in adults. It is characterised by involvement of the macular region of the retina with progressive neurodegeneration, which affects patients’ central vision function [7]. AMD is a chronic and progressive disease that can be classified clinically into four stages according to the Age-Related Eye Disease Study (AREDS) scale: stage 1 (early, up to a few small drusen with a diameter of < 63 μm), stage 2 (early, many small drusen with a diameter of < 63 μm, several drusen with a diameter of 63–125 μm or retinal pigment epithelium abnormalities), stage 3 (intermediate, many medium-sized drusen, at least one large drusen > 125 μm, geographic atrophy [GA], but not in the centre of the macula), and stage 4 (advanced, GA in the fovea) [8, 9]. Risk factors associated with increased incidence are diet, cigarette smoking, age, and ethnic group [10].
It has also been noted that genetics is an important factor influencing the occurrence of macular degeneration [11].
AMD can be present in two different forms: dry and wet. Typical findings in the dry type are drusen, i.e. areas of meta bolic waste accumulated under the retina, which impair the photoreceptor function and lead to degradation and atrophy [12]. Dry AMD can evolve into the wet form. Wet AMD is characterised by severe central vision loss caused by intense neovascularisation and increased permeability of blood vessels, which leads to intraretinal and subretinal fluid leaks [13].
The wet form can be treated effectively with anti-vascular endothelial growth factor (VEGF) intravitreal injections. Unfortunately, when it comes to dry AMD, no effective treatment method has been established yet. The only commonly available strategy includes daily antioxidative substances supplementation [14].

High plasma concentration of xanthophyll pigments, including lutein and zeaxanthin, is correlated with lower risk of the disease. They act as filters absorbing blue light and reducing reactive oxygen species production, which damages the retina [15]. Lutein is a carotenoid that accumulates specifically in the retinal macular area [16]. The human body is not capable of lutein synthesis and must obtain it from food. However, oral intake of lutein is limited by dietary preferences, variable absorption in the gastrointestinal system, and additional supplementation [17].
Lutein has been proven to delay the progression of the dry AMD into more advanced stages and allowed patients to preserve acceptable visual acuity for a longer periods of time [16]. Moreover, it was confirmed that lutein acts as a strong antioxidative factor [18]. Contrast sensitivity is one of the visual function parameters correlating with patients’ quality of life. It was described that AMD patients experience contrast sensitivity impairments [19].

The main aim of this study is to establish the impact of a novel method – transscleral lutein administration using iontophoresis – on patients with dry AMD. It could potentially increase lutein penetration into the macular region and stabilise or decrease the progression of AMD. This is a pilot prospective study performed on a small group.

Material and methods

The study was performed on 10 volunteer patients from the Ophthalmology Clinic at the Ophthalmic Uni­versity Hospital (SPKSO) in Warsaw, Poland. The study group included seven patients with dry AMD (AREDS stages 2 or 3) and three patients with GA (AREDS stage 4) involving the macular region.

Inclusion criteria: age > 45 years, refraction error between –4.0 D and +6.0 D, dry AMD AREDS stage > 1, limited dietary intake of lutein or zeaxanthin rich food (no more than two servings per week).

Exclusion criteria: previous anti-VEGF treatment, wet AMD, presence of choroidal neovascularisation, smoking more than 20 cigarettes per week, pregnancy, ocular media opacities, dense cataract, acute or chronic inflammation in the region of the eye, corneal scars or abrasions, advanced dry eye syndrome, ocular interventions other than cataract surgery in medical history, cataract surgery less than three months prior to the planned intervention, using medications with known effect on the eyes or visual acuity, scleral or retinal diseases other than AMD.

Patients were examined before the intervention, on the day of the intervention, one week after the intervention, and one month after the intervention.

Each patient was examined with complex ophthalmological evaluation including slit-lamp examination, eye fundus examination, AREDS scale assessment, and distance and near best corrected visual acuity (BCVA) assessment, based on an Early Treatment Diabetic Retinopathy Study chart and Snellen chart, intra ocular pressure (IOP) measurement with Goldmann applanation tonometry, and contrast sensitivity measurement based on a Pelli-Robson chart. Analysis of the macular region morphology, central macular thickness, drusen area, and drusen volume changes were measured and calculated with optical coherence tomography (OCT) using a Zeiss® Cirrus 5000.

To obtain IOP measurements, patients’ eyes were anaesthetised with proxymetacaine. Before slit lamp fundus examination, patients’ eyes were dilated with tropicamide.

Ten eyes were enrolled in the study (one eye per patient). Each patient was examined before the transscleral iontophoresis procedure and the eye presenting with more advanced AREDS stage (based on drusen number and area) was included.
Six right eyes and four left eyes were included.

Transscleral lutein iontophoresis single-use sets and a multiuse K-IONO kit and device were obtained from InView Medical, manufactured by OFFHEALTH SpA, Italy. Each set consisted of a single-use patch return electrode, ocular applicator for transscleral iontophoresis, a pre-filled syringe containing 2 ml of LIPO+, and a liposomal hypotonic solution of lutein. The K-IONO kit included a GK-IONO power generator, connection cable, and charger.

To perform the process of application, the K-IONO device was set to an intensity of 2.5 mA and duration of four minutes. Patients were anaesthetised regionally with proxymetacaine eyedrops. Then the patient’s forehead was cleansed with a 90% solution of alcohol. The return electrode was applied using the adhesive side and connected to the K-IONO device. The applicator was then attached to the device, placed on the patient’s eye and filled completely with the lutein solution. After that, the procedure was started. When the timer reached zero, the applicator was removed from the eye and excess lutein solution was rinsed with a 10-millilitre syringe filled with a balanced saline solution. The patient remained in a resting position for up to five minutes.

Statistical analysis was performed with the JASP® statistics program. Normality of data distribution was assessed using the Shapiro-Wilk test. Group comparisons were performed using Student’s t test or the Wilcoxon signed-rank test, depending on whether the assumption of normality was met. P-values less than 0.05 were considered statistically signi ficant.

Bioethical standards

The study was approved by the Bioethics Committee of the Medical University of Warsaw (Approval No. KB/105/2025). All par­ticipants gave written informed consent to participate in the study.

Results

Ten patients participated in this study: two men and eight women. Their mean age was 73.7 ±8.3 years, mean height was 166.6 ±6.88 cm, and mean body weight was 76.2 ±16.94 kg. Mean body mass index was 27.25 ±4.68. All patients presented with AREDS stage 2 or higher.

Five patients presented with distance BCVA improvement, four patients with no change and one patient with deterioration (Table I). However, changes in distance BCVA before transscleral iontophoresis and one month after were not statistically significant 0.35 ±0.36 vs. 0.34 ±0.33 (p = 0.735) logarithm of the minimum angle of resolution. Additionally, there were no statistically significant changes in near BCVA 0.7 ±0.48 vs. 0.65 ±0.47 (p = 1.00) Snellen. Also, there were no changes in IOP before and after the procedure 13.2 ±2.09 vs. 14.2 ±1.87 (p = 0.307) mmHg (Table II).
Contrast sensitivity measured before and after the intervention presented statistically significant improvement from 1.2 ±0.27 to 1.34 ±0.29 (
p = 0.022) logarithm of contrast sensitivity. No significant adverse effects were reported during the follow-up period.

Mean central macular thickness decreased after one-month post lutein administration, but not significantly (p = 0.411) (Figure 1).

Drusen parameters were calculated based on OCT device built-in program capabilities. Drusen area in 3 mm circle (p = 0.671) and 5 mm circle (p = 0.799), and drusen volume in 3 mm circle (p = 1.000) and 5 mm circle (p = 0.583) did not change significantly during the observation period (Figure 2).

No statistically significant changes (p < 0.05) in any parameter evolution were found in the GA patient subgroup. No side effects other than temporary irritation or lacrimation were noted. No patient resigned from the study.

Discussion

In this study, transscleral iontophoresis was confirmed as a safe and well tolerated method; no significant increases in intraocular pressure were noted, confirming a short-term safety profile. This is consistent with other studies, in which safety and tolerability were also confirmed, with no persistent changes in ocular surface after the procedure [20, 21].

Some improvements in distance BCVA were described in 50% of patients; however, they were not statistically significant. Similarly, no significant changes in near BCVA were detected. Those findings suggest that during the one-month follow-up period, no measurable changes occurred in patient visual acuity, despite some subtle individual improvements. This absence of statistically significant improvement might be explained by the progressive nature of dry AMD and short follow-up period. Other authors also did not report any improvement in BCVA in their research, despite a longer, six-month observation period compared to this study [20, 22].

To our best knowledge, this is the first study to measure contrast sensitivity after transscleral lutein iontophoresis. Contrast sensitivity demonstrated a significant improvement after the intervention was performed. These findings suggest that there is a beneficial effect in the functional area, even without improvements in BCVA. This is consistent with the Wolf-Schnurrbusch et al. study [23], in which contrast sensitivity increased significantly (1.29 ±0.25 to 1.69 ±0.22, p < 0.01) one month after lutein supplementation. In another randomised study, a group given daily supplementation of lutein presented with statistically higher contrast sensitivity compared to the placebo group, supporting the thesis that lutein could directly influence and improve visual function [24].

Central macular thickness (CMT) decreased non-significantly from 243.2 μm to 241.6 μm, which is consistent with the disease’s natural course and may vary with severity [25]. In another transscleral lutein study, CMT decreased from 273.2 μm to 270.87 μm (p = 0.411), which is consistent with our observations [22]. Moreover, a study by Grisso et al. [26] presented that macular thickness in intermediate AMD might vary with progression and drusen deposits, which can promote thinning. In research by Etheridge et al. [27], central circle thickness remained stable with age, but perifoveal thickness decreased. Mehkri et al. [28] described that CMT increased after lutein and zeaxanthin supplementation, with no change in the placebo group; however, their observation period was six times longer than ours.

The drusen area in 3 mm and 5 mm circles reduced from 0.60 mm2 to 0.58 mm2 and from 1.2 mm2 to 1.08 mm2 (p = 0.671 and p = 0.799), respectively, but not significantly. Normally, drusen tend to increase their area in a time-dependent manner during the follow-up period [29]. Another study proved that larger extension of drusen, reaching a 5 mm circle, was associated with development of more advanced disease stages [30]. This means that all interventions decreasing the drusen area in a 5 mm circle potentially have a protective effect on the macula. Additionally, an increase in drusen area and volume is a risk factor for GA progression [31]. Valldeperas et al. [32] reported that after 12-month lutein supplementation, the drusen area remained constant, which implies a potentially stabilising effect of lutein administered orally on AMD progression.

Our study showed a very small increase in drusen volume in a 3 mm circle with a decrease in a 5 mm circle from 0.022 to 0.023 and from 0.042 to 0.038 (p = 1.000 and p = 0.583), respectively; both not statistically significant. Drusen volume is a known risk factor for AMD progression, with a volume higher than 0.03 mm3 in the 3 mm circle, acting as an important early detection component [33]. It also showed a tendency to increase in AMD eyes over years of follow-up [34]. Oral lutein supplementation was associated with a non-significant increase in drusen volume during a one-year observation period, which implies a protective effect in slowing disease evolution [32].

Additionally, we did not report any improvement in the GA subgroup. Other authors have suggested that lutein supplementation could slow down the progression of GA; however, the follow-up period was extended up to three years, compared to the one-month observation in our study [35].

Our results are consistent with other authors’ findings showing that lutein intake mostly sustains the current disease status and inhibits progression in decreasing macular parameters, rather than improving them. However, a significant beneficial impact of transscleral lutein iontophoresis on contrast sensitivity was discovered.

These findings suggest that transscleral lutein is a promising strategy for slowing disease progression and maintaining sufficient visual functions, and could possibly be more effective when compared to oral lutein intake. A limitation of the study is the short observation period. Transscleral lutein iontophoresis requires further research to fully establish its potential.

Conclusions

In conclusion, transscleral iontophoresis was confirmed to be a safe method of lutein delivery in patients with dry AMD. Statistically significant improvement was reported in contrast sensitivity among the examined patients, but no significant improvements were found in BCVA, CMT, drusen area, and drusen volume. The presented results indicate that transscleral iontophoresis might stabilize or even enhance patients’ visual function, despite obvious morphological changes.

However, research including a larger cohort of patients, a control group, and a longer observation period is necessary to fully evaluate the potential of transscleral lutein iontophoresis to inhibit progression and improve visual parameter function in dry AMD disease.

Limitations

A major limitation of this study is the small sample size. Due to the pilot nature of the research, it was limited to only 10 participants. Hence, the final conclusions based on the achieved outcomes might have an increased risk of bias and should be interpreted with caution. To strengthen the evidence, a longer observation period and a larger patient group would be necessary.

Disclosures

Transscleral lutein iontophoresis single-use sets and multiuse K-IONO kit and device were obtained from InView Medical company free of charge.

The authors declare no other conflicts of interests.

The study was approved by the Bioethics Committee of the Medical University of Warsaw (Approval No. KB/105/2025).

References


  1. Myles M, Neumann D, Hill J. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005; 57: 2063-2079.
  2. Perez VL, Wirostko B, Korenfeld M, et al. Ophthalmic drug delivery using iontophoresis: recent clinical applications. J Ocul Pharmacol Ther 2020; 36: 75-87.
  3. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev 2004; 56: 619-658.
  4. Molokhia S, Papangkorn K, Butler C, et al. Transscleral iontophoresis for noninvasive ocular drug delivery of macromolecules. J Ocul Pharmacol Ther 2020; 36: 247-256.
  5. Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother 2018; 107: 1564-1582.
  6. Lombardo M, Villari V, Micali N, et al. Assessment of trans-scleral iontophoresis delivery of lutein to the human retina. J Biophotonics 2018; 11. DOI: 10.1002/jbio.201700095.
  7. Marchesi N, Capierri M, Pascale A, Barbieri A. Different therapeutic approaches for dry and wet AMD. Int J Mol Sci 2024; 25: 13053. DOI: 10.3390/ijms252313053.
  8. Deng Y, Qiao L, Du M, et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis 2021; 9: 62-79.
  9. Wąż P, Zorena K, Murawska A, Bielińska-Wąż D. Classification maps: a new mathematical tool supporting the diagnosis of age- related macular degeneration. J Pers Med 2023; 13: 1074. DOI: 10.3390/jpm13071074.
  10. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014; 2: e106-e116. DOI: 10.1016/S2214-109X(13)70145-1.
  11. Antoniak K, Bienias W, Nowak JZ. Zwyrodnienie plamki związane z wiekiem (AMD) – choroba o wieloczynnikowym podłożu genetycznym [Age-related macular degeneration – a complex genetic disease]. Klin Oczna 2008; 110: 211-218.
  12. Śpiewak D, Drzyzga Ł, Dorecka M, Wyględowska-Promieńska D. Summary of the therapeutic options for patients with dry and neovascular AMD. J Clin Med 2024; 13: 4227. DOI: 10.3390/jcm13144227.
  13. Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA 2024; 331: 147-157.
  14. Cabral de Guimaraes TA, Daich Varela M, Georgiou M, Michaelides M. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. Br J Ophthalmol 2022; 106: 297-304.
  15. Merle BMJ, Cougnard-Grégoire A, Korobelnik JF, et al. Plasma lutein, a nutritional biomarker for development of advanced age- related macular degeneration: the alienor study. Nutrients 2021; 13: 2047. DOI: 10.3390/nu13062047.
  16. Mrowicka M, Mrowicki J, Kucharska E, Majsterek I. Lutein and zeaxanthin and their roles in age-related macular degeneration – neurodegenerative disease. Nutrients 2022; 14: 827. DOI: 10.3390/nu14040827.
  17. Berendschot TT, Goldbohm RA, Klöpping WA, et al. Influence of lutein supplementation on macular pigment, assessed with two objective techniques. Invest Ophthalmol Vis Sci 2000; 41: 3322-3326.
  18. Jędrzejczak-Pospiech K, Błaszczyk J. The effect of lutein on the total antioxidant status in human blood. Klin Oczna 2017; 119: 220-223.
  19. Maganti N, Squires N, Mishra S, et al. Contrast sensitivity testing in age-related macular degeneration using motion diamond stimulus. Clin Ophthalmol 2022; 16: 507-515. DOI: 10.2147/OPTH.S342188.
  20. Rinaldi M, Cennamo G, Fioretto G, et al. Scleral iontophoresis for targeted lutein delivery in intermediate stage dry AMD: is this a new frontier in age macular degeneration? Photodiagnosis Photodyn Ther 2026; 57: 105356. DOI: 10.1016/j.pdpdt.2026.105356.
  21. Lombardo M, Serrao S, Lombardo G. Challenges in age-related macular degeneration: from risk factors to novel diagnostics and prevention strategies. Front Med 2022; 9: 887104. DOI: 10.3389/fmed.2022.887104.
  22. Mastropasqua R, Quarta A, Passamonti M, et al. Macular pigment optical density following lutein scleral iontophoresis in intermediate age-related macular degeneration: a six-month pilot study. Br J Ophthalmol 2026; 110: 899-906.
  23. Wolf-Schnurrbusch UEK, Zinkernagel MS, Munk MR, et al. Oral lutein supplementation enhances macular pigment density and contrast sensitivity but not in combination with polyunsaturated fatty acids. Invest Ophthalmol Vis Sci 2015; 56: 8069-8074.
  24. Machida N, Kosehira M, Kitaichi N. Clinical effects of dietary supplementation of lutein with high bio-accessibility on macular pigment optical density and contrast sensitivity: a randomized double-blind placebo-controlled parallel-group comparison trial. Nutrients 2020; 12: 2966. DOI: 10.3390/nu12102966.
  25. Chiang TTK, Keenan TD, Agrón E, et al. Macular thickness in intermediate age-related macular degeneration is influenced by disease severity and subretinal drusenoid deposit presence. Invest Ophthalmol Vis Sci 2020; 61: 59. DOI: 10.1167/iovs.61.6.59.
  26. Grisso P, Pak JW, Silva TD, et al. Correlations between AMD severity and OCT thickness. Invest Ophthalmol Vis Sci 2021; 62: 313-313.
  27. Etheridge T, Liu Z, Nalbandyan M, et al. Association of macular thickness with age and age-related macular degeneration in the carotenoids in age-related eye disease study 2 (CAREDS2), an ancillary study of the women’s health initiative. Transl Vis Sci Technol 2021; 10: 39. DOI: 10.1167/tvst.10.2.39.
  28. Mehkri S, Thirumalesh MB, Krishnaiah MV, et al. The effects of lutein and zeaxanthin (Lute-gen®) supplementation, with and without natural mixed carotenoids on macular pigment optical density in healthy adult subjects: a randomized, double-blind, placebo-controlled study. Int J Ophthalmol Res 2022; 4: 1-5.
  29. Yehoshua Z, Wang F, Rosenfeld PJ, et al. Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. Ophthalmology 2011; 118: 2434-2441.
  30. Kim TR, Kim TG, Choi J, et al. Quantitative analysis of drusen in Korean patients: a 36-month follow-up study. Korean J Ophthalmol 2025; 40: 87-98.
  31. Heesterbeek TJ, Lorés‐Motta L, Hoyng CB, et al. Risk factors for progression of age‐related macular degeneration. Ophthalmic Physiol Opt 2020; 40: 140-170.
  32. Valldeperas X, Romera P, Abos-Herrandiz R, Sabala A. Drusen morphology changes in nonexudative age-related degeneration using spectral domain optical coherence tomography after oral antioxidants supplementation: one-year results. Invest Ophthalmol Vis Sci 2015; 56: 5157-5157.
  33. Abdelfattah NS, Zhang H, Boyer DS, et al. Drusen volume as a predictor of disease progression in patients with late age-related macular degeneration in the fellow eye. Invest Ophthalmol Vis Sci 2016; 57: 1839-1846.
  34. Folgar FA, Yuan EL, Sevilla MB, et al. Drusen volume and retinal pigment epithelium abnormal thinning volume predict 2-year progression of age-related macular degeneration. Ophthalmology 2016; 123: 39-50.e1. DOI: 10.1016/j.ophtha.2015.09.016.
  35. Keenan TDL, Agrón E, Keane PA, et al. Age-related eye disease study research group, et al. Oral antioxidant and Lutein/Zeaxanthin supplements slow geographic atrophy progression to the fovea in age-related macular degeneration. Ophthalmology 2025; 132: 14-29.
Udostępnij
without publication fees
without publication fees